PubMed Health⌕ Search

Biomedical subjects

P Gallurt

Publications and source records attributed to P Gallurt.

6 recordsLinked to original sources
PubMed1988

Biological changes in serum antiproteases as related to tumor progression.

The two major antiproteases (alpha-1-antitrypsin and alpha-2-macroglobulin) were studied in the serum of cancer patients (273 and 103 subjects, respectively) and in a control group. In cancer patients, the values were stratified by clinical stage (local, loco-regional and metastatic disease). Serum alpha-1-antitrypsin was different in normal people (341 +/- 110.7 mg/dl) than in every cancer group (p less than 0.0005). The behavior of alpha-2-macroglobulin was similar, with significant differences (p less than 0.0005) between normal people (317.6 +/- 105.4 mg/dl) and the cancer groups. Serum alpha-1-antitrypsin was different in local, loco-regional and metastatic disease; however, alpha-2-macroglobulin did not show these differences. In metastatic disease, sensitivity was 96.66% for alpha-1-antitrypsin and 94.79% for alpha-2-macroglobulin.

Female↗
PubMedDate not supplied

ROC analysis of diagnostic performance utilizing serum antiproteases in cancer patients.

Assessment of the accuracy of diagnostic procedures is made independent of diagnostic criteria by means of a receiver-operating-characteristics (ROC) curve. We performed ROC analysis for the major serum antiproteases: alpha-1-antitrypsin (A1AT) and alpha-2-macroglobulin (A2M), in 99 cancer patients compared with 71 normal individuals. A1AT and A2M were significantly higher in cancer patients (p less than 0.0005). By comparing true positive and false positive rates for different serum levels, ROC analysis showed that serum A1AT quantification seems more useful in clinical practice than serum A2M.

Adult↗
PubMedDate not supplied

Plasmatic fibronectin in malignancies.

Plasmatic fibronectin has been studied in tumor patients on the basis of the role that unspecific opsonin may play in tumor growth and spreading. Alterations in fibronectin levels might be used as a biological marker and our purpose has been to evaluate the significance of this test in the biological diagnosis of cancer. When comparing the levels found in the control group (22.86 +/- 1.40 mg/dl) and in tumor patients (23.80 +/- 1.90 mg/dl), we observed no difference in the overall group. However, in relation to the localization of tumors, a significant increase was found in breast cancer (31.83 +/- 3.83 mg/dl) and a significant decrease in squamous cell carcinoma of the head and neck (9.56 +/- 1.68 mg/dl). These results suggest that plasmatic fibronectin could be useful as a biomarker in some types of tumors. Our conclusion was confirmed by analysis of ROC curves related to every one of the studied tumors.

Adolescent↗